Reaction
Gastrointestinal Oedema reporting signals
As of the last recalculation, Gastrointestinal Oedema appears in 1,743 FAERS reports alongside 24 co-occurring drug terms. The strongest observed disproportionality signal is REGORAFENIB (PRR 13.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Regorafenib | 13 | 13.5 | 13.5 |
| Teduglutide | 13 | 11.6 | 11.6 |
| Anti-Thymocyte Globulin (Rabbit) | 7 | 10.4 | 10.4 |
| Mesalamine | 47 | 10.2 | 10.3 |
| Lubiprostone | 8 | 10.1 | 10.2 |
| Isotretinoin | 41 | 10.1 | 10.1 |
| Mercaptopurine | 12 | 8.3 | 8.3 |
| Febuxostat Tablets 40 Mg | 7 | 8.2 | 8.3 |
| Febuxostat Tablets 80 Mg | 7 | 8.2 | 8.3 |
| Adalimumab | 380 | 7.9 | 7.9 |
| Posaconazole Delayed-Release | 7 | 7.6 | 7.6 |
| Meropenem | 18 | 6.8 | 6.8 |
| Tolvaptan | 8 | 6.6 | 6.6 |
| Oxaliplatin | 32 | 5.2 | 5.2 |
| Eltrombopag Olamine | 9 | 4.7 | 4.7 |
| Iohexol | 3 | 4.3 | 4.3 |
| Voclosporin | 3 | 4.1 | 4.1 |
| Pembrolizumab | 35 | 4.0 | 4.0 |
| Pazopanib Hydrochloride | 9 | 4.0 | 4.0 |
| Crizotinib | 4 | 3.8 | 3.8 |
| Fam-Trastuzumab Deruxtecan-Nxki | 3 | 3.6 | 3.6 |
| Ipilimumab | 12 | 3.3 | 3.3 |
| Lenvatinib | 9 | 3.3 | 3.3 |
| Salicylic Acid | 4 | 0.9 | 0.9 |